Measurement of FeNO in Young Children With the NIOX VERO

Asthma Clinical Trial

Official title:

A Randomized, Multi-Center, Single-Visit, Clinical Investigation to Assess the Degree of Agreement and Feasibility of Measuring Exhaled Nitric Oxide in Children, Aged 4-6 Years Old, With the NIOX VERO Using the 6 Second Exhalation Mode as Compared With the 10 Second Exhalation Mode

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02661984
• Other study ID #: AER-052
• Status: Active, not recruiting
• Phase: N/A
• First received: January 5, 2016
• Last updated: May 11, 2017
• Start date: January 2016
• Est. completion date: May 31, 2017

Study information

• Verified date: May 2017
• Source: Aerocrine AB
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

FeNO measurements provide the physician with means of evaluating an asthma patient's response to anti-inflammatory therapy, as an adjunct to the established clinical and laboratory assessments in asthma. Interpretation of FeNO profiles is based on the nitric oxide plateau. To achieve plateau, the duration of exhalation must be sufficient (at least 4 seconds for children <12 years and > 6 seconds for children > 12 years (ATS/ERS, 2005).

Measurement of FeNO using the 6-sec mode may provide a viable alternative in children as young as age 4 years who may have difficulty maintaining exhalation for a full 10 seconds.

Description:

The primary objective is to assess the degree of agreement of FeNO measured with the NIOX VERO using the 6-sec and 10-sec modes.

The secondary objectives of the Clinical Investigation are to:

• Assess the ability of participants to use the NIOX VERO for measuring FeNO in both exhalation modes, and

• Compare the repeatability of FeNO measured with the NIOX VERO in both exhalation modes.

Participants will attempt 2 measurements taken using the 6-sec mode followed by 2 measurements using the 10 second exhalation mode or vice versa.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 102
• Est. completion date: May 31, 2017
• Est. primary completion date: November 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 4 Years to 6 Years

Eligibility

Inclusion Criteria:

1. Male or female 4, 5 and 6 years old,

2. Primary Language: English or Spanish, and

3. Healthy (e.g., no pulmonary disease) or Asthmatic (if asthmatic, they must have a physician diagnosis of asthma).

Exclusion Criteria:

1. Pulmonary Disease Status: Any disease other than asthma.

2. In the opinion of the investigator, has severe or uncontrolled asthma (defined as having a) 2 or more exacerbations within the last year that required the use of systemic corticosteroids, or b) 1 or more hospitalizations, ICU stays or mechanical ventilations within the last year).

3. Has taken their reliever inhaler within 4 - 6 hours from the FeNO measurements.

4. Has acute asthma symptoms, respiratory illness (e.g. cold, flu), or sinusitis.

5. Has had food or beverage intake (other than water) or has participated in strenuous exercise within 1 hour prior to FeNO measurement.

6. Has a family relationship with the Operator or Study Personnel (persons who are family members of the Operator or Study Personnel are not eligible to participate).

7. Has a Parent/Guardian who is unable or unwilling to provide informed consent.

Related Conditions & MeSH terms

• Asthma

Locations

Country	Name	City	State
United States	Allergy and Asthma Specialists	Blue Bell	Pennsylvania
United States	Allergy Partners of North Texas	Dallas	Texas
United States	Arizona Allergy & Immunology Research	Gilbert	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Aerocrine AB

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint will be the analysis of the agreement of successful FeNO measurements in the 10 second and the 6 second exhalation modes.	This is a single visit study.	After a single 1-2 hour visit